CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Bill Would Remove Financial Penalties for Participating in Research Studies
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
Bill Would Remove Barrier to Clinical Research for Rare Diseases by Ensuring that Clinical Trial Participants Don't Lose Critical Health Benefits
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Observational study supported by the CF Foundation will monitor real-world experience with Trikafta
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.